BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05961839 (SGR-2921 in Relapsed/​Refractory Acute Myeloid Leukemia or Myelodysplastic…): BVCT ex-ante prediction vs. reported outcome

On 6 Aug 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 14 Aug 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05961839
Drug Name
SGR-2921
Drug MoA
CDC7 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Relapsed/​Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Human Patients
66
Sponsor
Schrödinger
Phase
Phase 1

Prediction of , index 1721

Prospective Prediction
Prediction Index
1721
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient (additive) clinical benefit in OS)
Technical Prediction
FAILURE (statistically insignificant (additive) clinical benefit in ORR/PFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
373 days in advance
Readout Data Interpretation
SGR-2921’s further development has been discontinued due to unfavourable clinical benefit/risk profile
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase
Phase 1
Status
Terminated
Enrollment
66
Lead sponsor
Schrödinger, Inc.
Conditions
Acute Myeloid Leukemia; High-Risk and Very High-Risk Myelodysplastic Syndromes
Interventions
DRUG: SGR-2921
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2023-09-27
Primary completion
2025-08-14
Completion
2025-09-09
Primary outcomes
  • Dose Limiting Toxicities (From first dose until the end of Cycle 1 (approximately 28 days, up to 42 days).)
  • Adverse Events (Throughout the study, up to 26 months.)
  • Electrocardiograms in Singlicate and Triplicate (Throughout the study, up to 26 months.)

NCT05961839 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials